The business combination is expected to close in the first quarter of 2024
Save time and jump to the most important pieces.
SC 13G/A - PowerUp Acquisition Corp. (0001847345) (Subject)
SC 13G - PowerUp Acquisition Corp. (0001847345) (Subject)
SC 13G/A - PowerUp Acquisition Corp. (0001847345) (Subject)
PowerUp Acquisition Corp. (the "Company") (NASDAQ:PWUP) announced today that, on June 3, 2024, the Company received a notice (the "Notice") from the Nasdaq Listing Qualifications Department ("Nasdaq") indicating that the Company was not compliant with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission ("SEC").
10-Q - PowerUp Acquisition Corp. (0001847345) (Filer)
10-Q/A - PowerUp Acquisition Corp. (0001847345) (Filer)
10-Q/A - PowerUp Acquisition Corp. (0001847345) (Filer)
3 - PowerUp Acquisition Corp. (0001847345) (Issuer)
3 - PowerUp Acquisition Corp. (0001847345) (Issuer)
3 - PowerUp Acquisition Corp. (0001847345) (Issuer)
Highlights Transaction Valuation: The transaction values Aspire Biopharma, Inc. at a pre-money equity value of approximately $316 million.Industry-Leading Platform: Aspire is focused on developing a pipeline of products utilizing its novel delivery mechanisms to enhance the efficacy of "do no harm" FDA approved drugs, nutraceuticals and supplements.Innovative Drug Delivery Technology: Aspire's patented and patent-pending delivery system includes components specifically formulated to allow rapid sublingual absorption of drugs directly into the blood stream, thus on first pass, avoiding the gastrointestinal tract and liver, mitigating unwanted toxicity of this critical organ.Growth and
Humacao, PR and New York, NY, July 31, 2024 (GLOBE NEWSWIRE) -- Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent protected disruptive drug delivery mechanism technology, and PowerUp Acquisition Corp. (NASDAQ:PWUP), a Nasdaq Global Market® listed special purpose acquisition company ("PowerUp"), today announced that they have signed a non-binding letter of intent ("LOI") for a potential business combination ("Business Combination"). Under the terms of the LOI, following the consummation of the Business Combination, the combined public company would be listed on a national securities exchange. Aspire Biopharma, Inc. is a privately held, early-stag
New York, NY, June 05, 2024 (GLOBE NEWSWIRE) -- PowerUp Acquisition Corp. (the "Company") (NASDAQ:PWUP) announced today that, on June 3, 2024, the Company received a notice (the "Notice") from the Nasdaq Listing Qualifications Department ("Nasdaq") indicating that the Company was not compliant with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission ("SEC"). The Notice indicates that the Company must, no later than August 2, 2024, submit a plan to regain compliance with respect to the filing requirement. Followi